New Medical Journal Article Presents “Compelling Evidence” That These Newer Oral Contraceptives Are Associated With More Venous Thromboembolism Events
SUMMARY: From an Editorial piece published May 26, 2015 by the medical journal BMJ, “Fresh evidence confirms links between newer contraceptive pills and higher risk of venous thromboembolism”, we get this commentary from Susan S. Jick, of Boston University School of Public Health):
Notably, Vinogradova and colleagues also looked at the newer oral contraceptives, such as those containing desogestrel, gestodene, and cyproterone, as well as the newest pill containing drospirenone, where data have been limited and the magnitude of effects on the risks of venous thromboembolism remains controversial…. Vinogradova’s comprehensive study addresses important questions about the risk of venous thromboembolism in women taking oral contraceptives, concluding that the risk associated with newer pills is around twofold higher than the risk associated with older contraceptives.
The important new medical study that Dr. Jick is alluding to above is the subject of this article, “Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases”, published in the same edition of the BMJ medical journal.
Beyaz, Safyral, YAZ, and Yasmin are birth control pills which contain ethinyl estradiol (EE) and the progestin drospirenone (DRSP). These DRSP oral contraceptives have been associated with several different adverse side effects such as:
• Blood Clots
• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Stroke or Cerebrovascular Accidents (CVA)
• Heart Attack or Myocardial Infarction
We will continue to watch for legal, medical, and regulatory developments as regards Beyaz, Safyral, YAZ, and Yasmin, as well as other DRSP birth control pills such as Gianvi and Ocella.[Read this article in full at original source]
Strictly Confidential, No Obligation.